Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

doi:10.3748/wjg.v21.i38.10874

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7258)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

418

WORD

276

HTML

3251

Figures (1-5)

139

Tables (1-4)

123

Sum=4207

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1150

Download

1901

Sum=3051

Oct 14, 2015 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Oct 14, 2015; 21(38): 10874-10882
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10874

Table 2 Comparison of clinical features between groups according to 1-year virologic response n (%)

	Patients without VR (n = 32)	Patients with VR (n = 18)	P value
Age (yr)¹	47 (22-70)	42.5 (33-74)	0.413
Male	22 (68.8)	15 (83.3)	0.328
HBeAg-positive	31 (96.9)	16 (88.9)	0.291
Cirrhosis	8 (25)	4 (22.2)	1.000
Duration of ETV therapy (mo)¹	24 (13-48)	36 (17-58)	0.003
Serum ALT level (IU/L)¹	34.5 (12-918)	29 (5-1704)	0.210
Serum total bilirubin level (mg/dL)¹	0.84 (0.31-1.99)	0.79 (0.28-4.30)	0.869
Serum albumin level (g/dL)¹	4.2 (3.6-5.1)	4.3 (3.6-4.9)	0.691
INR¹	1.01 (0.93-1.23)	1.02 (0.87-1.30)	0.848
Serum HBV DNA level (log₁₀ IU/mL)¹	6.16 (3.85-7.63)	4.24 (2.81-7.08)	< 0.001
Site of ETV-resistant mutations			0.441
rt184	12 (37.5)	7 (38.9)
rt202	14 (43.8)	8 (44.4)
rt173	0 (0)	1 (5.6)
rt169 + rt184	0 (0)	1 (5.6)
rt184 + rt202	5 (15.6)	1 (5.6)
rt184 + rt250,	1 (3.1)	0 (0)
Presence of IVR-3	7 (21.9)	17 (94.4)	< 0.001
Rescue therapy regimens (ADV/LMV vs ADV/ETV)	19 vs 13 (59.4 vs 40.6)	8 vs 10 (44.4 vs 55.6)	0.382

¹Data are expressed as median (range). ADV: Adefovir; ALT: Alanine aminotransferase; ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; INR: International normalized ratio; IVR-3: Initial virologic response at 3 mo; LMV: Lamivudine; VR: Virologic response.

Citation: Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882
URL: https://www.wjgnet.com/1007-9327/full/v21/i38/10874.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i38.10874